Published January 2018 | Version v1
Journal article

1,25(OH)2D3 attenuates pulmonary arterial hypertension via microRNA-204 mediated Tgfbr2/Smad signaling

  • 1. Department of Geriatric Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, Zhejiang (China)
  • 2. Department of Respiratory Medicine, The First Affiliated Hospital, Wenzhou Medical University, Shangcai Village, South Baixiang town, Ouhai District, Wenzhou 325000, Zhejiang (China)
  • 3. School of Life Science, Wenzhou Medical University, Wenzhou 325000, Zhejiang (China)

Description

Highlights: • miRNA-204 is significantly lower in hypoxic pulmonary hypertension. • miRNA-204 is involved in the development of pulmonary hypertension. • 1,25(OH)2D3 significantly prevented the development of PAH by blocking the Tgfbr2/Smad signaling. • 1,25(OH)2D3 reduced pulmonary hypertension mediated by increased the level of miRNA-204. • miRNA-204 strengthened the anti-PAH function of 1,25(OH)2D3 by targeting Tgfbr2. Pulmonary arterial hypertension (PAH) is a devastating disease characterized by high pulmonary artery pressure. It is reported that microRNA-204 (miR-204) plays an important role in the development of PAH. Calcitriol [1,25-dihydroxyvitamin D3, 1,25(OH)2D3] mediates multiple pathophysiological processes. The aim of the current study was to explore the role of 1,25(OH)2D3 in PAH. PAH was induced in rats and rat pulmonary arterial endothelial cells (PAECs) were isolated as in vitro PAH model. The mean pulmonary artery pressure, morphologic changes, and expressions of transforming growth factor-beta1 (Tgfbr2), Smad2/7, alpha smooth muscle actin (α-SMA), and p21 were then measured. Furthermore, the effect of 1,25(OH)2D3 on rat PAECs with or without hypoxia treatment was also assessed by measuring the proliferation, migration, and cell cycle distribution of PAECs. The potential targets of miR-204 were also predicted and validated with a dual-luciferase reporter system. Then the role of miR-204 and Tgfbr2 in the anti-PAH effect of 1,25(OH)2D3 was further explored by modulating the expression of the two genes. The overall pulmonary hypertension and hypoxia-induced proliferation and migration of PAECs were attenuated by administration of 1,25(OH)2D3, which was associated with the suppressed expressions of Tgfbr2, α-SMA, and Smad7 and induced expressions of miR-204, p21 and Smad2 both in vitro and in vivo. Moreover, the luciferase reporter assay identified Tgfbr2 as a novel direct target of miR-204. Both overexpression of miR-204 and inhibition of Tgfbr2 would strengthen the effect of 1,25(OH)2D3 administration. Findings outlined in the current study demonstrated that 1,25(OH)2D3 was a promising therapeutic modality for treatment of PAH, function of which was exerted through miR-204 mediated Tgfbr2 signaling.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.yexcr.2017.11.032

Additional details

Identifiers

DOI
10.1016/j.yexcr.2017.11.032;
PII
S0014482717306353;

Publishing Information

Journal Title
Experimental Cell Research
Journal Volume
362
Journal Issue
2
Journal Page Range
p. 311-323
ISSN
0014-4827
CODEN
ECREAL

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
52123264
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
ACTIN; ANOXIA; ARTERIES; CELL CYCLE; GROWTH FACTORS; HYPERTENSION; IN VITRO; IN VIVO; LUCIFERASE; RATS
Descriptors DEC
ANIMALS; BLOOD VESSELS; BODY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASES; ENZYMES; MAMMALS; MITOGENS; ORGANIC COMPOUNDS; ORGANS; OXIDASES; OXIDOREDUCTASES; PROTEINS; RODENTS; SYMPTOMS; VASCULAR DISEASES; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2017 Elsevier Inc. All rights reserved.